FeraMAX® est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis neuf années consécutives
03 avr. 2024 08h00 HE
|
BioSyent Inc.
Mississauga (Ontario), 03 avr. 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer...
BioSyent to Present at LD Micro New York Investor Conference
01 avr. 2024 14h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be...
BioSyent Announces Grant of Restricted Share Units
27 mars 2024 18h34 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
13 mars 2024 17h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended...
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
06 mars 2024 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Named to 2024 TSX Venture 50
21 févr. 2024 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as...
BioSyent Declares First Quarter 2024 Dividend
06 févr. 2024 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Announces Renewal of Normal Course Issuer Bid
13 déc. 2023 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent Announces the Availability of Gelclair® in Canada
20 nov. 2023 08h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the...
BioSyent Releases Q3 and YTD 2023 Financial Results
16 nov. 2023 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended...